Boston Scientific (BSX) Plunges to 52-Week Low as Wall Street Adjusts Forecasts Pre-Earnings
Boston Scientific's stock plummeted to a 52-week low of $60.54, down 36% year-to-date, ahead of its Q1 2026 earnings release. Despite the decline, several Wall Street firms maintain Buy recommendations, citing robust revenue growth and undervaluation.
Boston Scientific's stock hit a 52-week low of $60.54 on April 21, representing a 36% year-to-date decline. The company's Q1 2026 financial results are scheduled for release on April 22. Analyst Rick Wise from Stifel reduced his price objective to $85 from $90, citing electrophysiology hospital purchasing trends. Despite this, several Wall Street firms maintain Buy recommendations, with RBC Capital and UBS forecasting prices of $115 and $105, respectively. InvestingPro has identified Boston Scientific as undervalued, with a Fair Value estimate of $76.66, approximately 27% higher than current market prices. The company has delivered nearly 20% revenue growth over the last twelve months.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.